טוען...
Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
Even though classical Hodgkin lymphoma is highly curable, the outcome of patients with a refractory or relapsed disease has been disappointing. Multiple lines of therapy are available for patients after their first failure, and most respond to subsequent therapies. However, there is a sizable propor...
שמור ב:
| הוצא לאור ב: | World J Oncol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elmer Press
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8297052/ https://ncbi.nlm.nih.gov/pubmed/34349851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/wjon1388 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|